ERBB2 and neoplasm: Another promising target for individualized therapy in advanced Her2-negative, Claudin-18.2-positive EGC (moderate-to-strong membrane staining in ≥75 % tumor cells) is the anti-Claudin-18.2 targeted antibody zolbetuximab (IMAB362), which specifically binds to the tight-junction component Claudin-18.2, which is expressed in malignant transformed gastric mucosa of diffuse and intestinal GC.